Abstract
In this editorial, we discuss the recent article by Regassa et al, published in the World Journal of Diabetes, which highlights the potential role of platelet indices (PI) in predicting poor glucoregulation in patients with type 2 diabetes mellitus (T2DM). Given the high morbidity and mortality associated with T2DM, there is a constant need to find new and accessible methods for predicting and treating individuals with this condition. The pathophysiology of T2DM involves systemic inflammation, metabolic dysfunction, and an increased risk of vascular injury, which are commonly associated with the development of microvascular and macrovascular complications, such as cardiovascular diseases and neuropathies. The link between these complications and T2DM requires further elucidation but may be explained by prolonged exposure to high glycemic levels and increased advanced glycation end products. PI might play an important role in determining whether some individuals are prone to poor glucoregulation. Recent evidence encourages the scientific efforts to demonstrate the consistency of this role and its applicability in monitoring glucoregulation, underscoring the importance of the study by Regassa et al.